Scottsdale, Arizona based, Regenesis Biomedical, Inc. has launch the new Provant® Infinity system that is available purchase for home use when prescribed by a health professional. Outcomes with Provant Therapy are documented in journal articles, white papers, and case reports. Provant relieves pain in several post-operative conditions, including orthopaedic surgery, joint replacement, amputation, rotator cuff repair, back surgery, hernia repair, debridement, hand and foot surgeries, and neuropathy.Continue reading
Author Archive: AZBio
Banner Alzheimer’s Institute gets $27.5M NIH grant for genetic risk study
Banner Alzheimer’s Institute (BAI) has received a grant expected to total $27.5 million over five years from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to further investigate biological and cognitive changes preceding the onset of memory and thinking problems in people at different levels of genetic risk for Alzheimer’s disease. Led by researchers from Banner and Mayo Clinic in Arizona, the five-year grant will study healthy people with six forms of the apolipoprotein E (APOE) gene, the major genetic risk factor for Alzheimer’s disease, create a shared scientific resource of data and biological samples to support a wide range of future studies, and help to advance the understanding, treatment, and prevention of Alzheimer’s disease.Continue reading
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma
In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1
Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution1
BD to Invest $65 Million for Key Supply Chain Infrastructure in Tucson, Arizona to Increase Resiliency of U.S. Medical Device Supply
TUCSON, Ariz., April 1, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company’s supply chain, serving as a final-stage manufacturing and sterilization center.
850 PBC Opens on the Phoenix Biomedical Campus
Located adjacent to ASU’s downtown campus, the Phoenix Biomedical Campus (PBC) Innovation Center expands the downtown biomedical corridor to the northern edges of the urban core. Designed to integrate research, entrepreneurial activity, and corporate engagement, the building offers opportunities for meaningful collaboration with the building tenants and community.Continue reading
UArizona Health Sciences, Cancer Center Launching Arizona Clinical Trials Network
Arizona residents, including underserved and underrepresented populations, will have better access to cutting-edge cancer therapies as the UArizona Cancer Center offers its clinical trials at locations across the state.Continue reading
AZBio Health Innovation Spotlight Public Information Campaign Kicks Off with Vaccine Information
The Sonoran Living Health Innovation Spotlight Public Information Campaign is designed to tackle one of our bioscience industry’s greatest challenges, the “Who Knew” Effect.
Arizona life science innovators are working to discover, develop, and deliver life saving and life changing innovations.
In 2021, AZBio is pleased to partner with ABC15 and CW61 to share quick Sonoran Living Health Innovation Spotlights during the morning and evening news hours along with longer segments on Sonoran Living periodically during 2021 to help our community learn more about the work of Arizona’s healthcare innovators. Each segment touches on a public health challenge or opportunity and spotlights an Arizona life science company’s work to create a solution.
Investigational AstraZeneca vaccine prevents COVID-19
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization. The independent Data and Safety Monitoring Board (DSMB) overseeing the trial identified no safety concerns related to the vaccine. The United Kingdom-based global biopharmaceutical company AstraZeneca developed the vaccine and led the trial as regulatory sponsor.Continue reading
Novel Coronavirus Circulated Undetected Months Before First COVID-19 Cases in Wuhan
A new study dates emergence of the virus that causes COVID-19 to as early as October 2019. Simulations also suggest that in most cases, zoonotic viruses die out naturally before causing a pandemic.Continue reading
NAU bioengineer partners with industry expert to launch successful spin-off commercializing mobility technologies
Company’s first prototype product—a lightweight, wearable robotic ankle assist device—is designed to grow with the patient, an innovation that meets a specific market needContinue reading